Home / Sector / Healthcare Shares / Regis Healthcare names Andrew Kinkade as new CEO
Free ArticleExplore Premium Services

Regis Healthcare names Andrew Kinkade as new CEO

Regis Healthcare appoints Andrew Kinkade as CEO, unveiling new leadership strategy and key remuneration details.

Posted by
Laura Stewart
Author bio Laura Stewart is a Finance Editor at The Motley Fool, where she covers Australian and international equity markets. She joined the company in 2022, following a career transition from legal advisory work in Southeast Asia into the investment industry. Prior to her current editorial role, Laura spent three years as an Equity Analyst and Writer, producing investment research across the ASX, NYSE, and NASDAQ. Her coverage included small-cap growth companies, thematic investment ideas, and high-quality U.S.-listed businesses. Laura holds a Master of Applied Finance and brings additional expertise in accounting, taxation, and estate and wealth planning from her postgraduate studies. She also has a background in law and communications, which supports her analytical and reporting work in financial markets. Outside of work, she enjoys spending time in the Adelaide Hills with her flock of sheep. Education Laura holds a Bachelor of Laws, a Bachelor of Communication (Journalism), and a Bachelor of Commerce with majors in Accounting and Corporate Finance. In 2025, she completed a Master of Applied Finance at the University of Adelaide, receiving postgraduate awards in Accounting Concepts & Methods, Ethical Principles in Accounting & Finance, Real Estate Valuation & Investment, and Tax, Estate & Wealth Planning. Social media LinkedIn FYI – I am taking a break from social media at the moment, so this account isn’t active at the moment, but I will let you know when I rejoin. Favorite investment quote "Compound interest is the eighth wonder of the world. He who understands it, earns it... he who doesn't... pays it." — Albert Einstein
Published

The Regis Healthcare Ltd (ASX: REG) share price is in focus today after the company announced the appointment of Andrew Kinkade as its new Managing Director and Chief Executive Officer. Kinkade joins Regis with an extensive leadership background in aged care, healthcare and finance.

CEO of a company talking.

Image source: Getty Images

What did Regis Healthcare report?

  • Appointment of Andrew Kinkade as new Managing Director & CEO, commencing 20 July 2026
  • Total fixed remuneration of $900,000 per annum, inclusive of superannuation
  • Short Term Incentive of up to 50% of TFR and Long Term Incentive of up to 100% of TFR, subject to performance
  • Sign-on equity award of $1.6 million in Performance Rights, subject to shareholder approval

What else do investors need to know?

Andrew Kinkade brings more than 20 years of experience across aged care, healthcare, private equity, and investment banking, most recently serving as Managing Director at Bupa Villages & Aged Care. He has been recognised for leading operational and cultural transformation, driving both growth and improved care standards.

Kinkade replaces Dr Linda Mellors, who will complete her notice period in June after leading the company for over six years. The board expressed its appreciation for Dr Mellors' significant contributions and steady leadership throughout her tenure.

What's next for Regis Healthcare?

Kinkade's appointment signals a focus on operational transformation and strengthening Regis's position in Australia's aged care sector. The Board noted his track record of leading growth in regulated, people-focused businesses, which aligns with Regis Healthcare's strategic objectives.

Shareholders will vote on key elements of Kinkade's remuneration package, including his sign-on equity award, at the upcoming Annual General Meeting. The company expects a smooth transition and ongoing delivery on its growth plans.

Regis Healthcare share price snapshot

Over the past 12 months, Regis Healthcare shares have declined 2%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 8% over the same period.

View Original Announcement

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

More on Healthcare Shares

Happy businessman fist pumping while looking at a tablet.
Healthcare Shares

Mesoblast wins FDA nod for new Ryoncil potency test

| Laura Stewart

Mesoblast gets FDA approval for a new Ryoncil potency assay, aiming to ensure quality and support product expansion.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces.
Healthcare Shares

Can CSL shares hit $200? 3 things that need to go right

| Marc Van Dinther

CSL needs to prove its earnings engine is accelerating again, not merely stabilising.

Read more »

Group of doctors celebrate by pumping fists in the air.
Healthcare Shares

Telix Pharmaceuticals vs Ramsay Healthcare: Which ASX healthcare stock made investors richer in 2026?

| Samantha Menzies

And find out which has the strongest upside ahead.

Read more »

Buy and sell written on red dice on top of stock market charts.
Broker Notes

Up 98%: Are CSL shares now a buy, hold or sell?

| Bernd Struben

A leading expert provides his forecast for CSL’s rocketing shares.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Broker Notes

What is this broker's view on Telix shares after yesterday's crash?

| Aaron Bell

Here is the latest outlook from Bell Potter.

Read more »

Doctor with stethoscope holding a tablet and smiling.
Healthcare Shares

How much could the CSL share price rise in the next year?

| Tristan Harrison

Can CSL continue delivering very healthy returns?

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Telix shares just crashed 12% on merger news. Time to buy the dip?

| Marc Van Dinther

Integration, regulatory milestones and dilution are the real tests now.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Sigma Healthcare vs Sonic Healthcare: Which ASX healthcare share wins?

| Laura Stewart

I compare Sigma Healthcare and Sonic Healthcare to reveal which ASX healthcare share I think is the better buy right…

Read more »